Cyclosporine Reduction in the Presence of Everolimus: 3-Month Data From a Canadian Pilot Study of Maintenance Cardiac Allograft Recipients

This pilot study suggests that initiation of concentration-controlled everolimus with a concomitant 25% reduction in CsA dose in maintenance heart transplant patients is associated with no significant decline in renal function, and no indication of increased rejection to Month 3 post-conversion. Evaluation of more substantial CsA dose reductions is required.